Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 7/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.61 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 8/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174976 | 0.76 | SCN2A (1.00) | SCN2ANPY5RHPGDS | |
| SCHEMBL7380282 | 0.76 | SCN2A (0.63) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL17283469 | 0.74 | SCN2A (0.96) | SCN2ANPY5RHPGDS | |
| SCHEMBL11013182 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL28542982 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL5371995 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL535044 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL16090411 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL236656 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL | |
| SCHEMBL10927029 | 0.74 | SCN2A (0.61) | SCN2ANPY5RPIN1HPGDSRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1621540-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | SCN2A 540/4885NPY5R 4162/4885PIN1 249/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | SCN2A 540/4885NPY5R 4162/4885PIN1 249/4885 |
| US-20070155713-A1 | Nitrogen-containing heterocyclic compounds and use thereof | NNMT, HLA-DRB1, NNT | SCN2A 2970/4885NPY5R 2803/4885PIN1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.